HC Wainwright Analysts Increase Earnings Estimates for KYTX

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Kyverna Therapeutics in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.62) per share for the quarter, up from their previous forecast of ($0.88). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.61) EPS.

A number of other brokerages have also recently issued reports on KYTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Morgan Stanley set a $33.00 target price on shares of Kyverna Therapeutics in a report on Monday, December 15th. Finally, Wells Fargo & Company boosted their price target on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Stock Up 13.9%

NASDAQ:KYTX opened at $8.63 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 7.75 and a quick ratio of 7.75. The firm’s 50-day moving average price is $8.26 and its 200-day moving average price is $7.69. The company has a market capitalization of $377.99 million, a PE ratio of -2.36 and a beta of 3.32. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80).

Institutional Trading of Kyverna Therapeutics

Several institutional investors have recently bought and sold shares of KYTX. Public Employees Retirement System of Ohio purchased a new position in shares of Kyverna Therapeutics during the third quarter valued at approximately $28,000. Qube Research & Technologies Ltd purchased a new stake in Kyverna Therapeutics in the second quarter worth approximately $43,000. Capital Advisors Inc. OK bought a new stake in Kyverna Therapeutics in the 3rd quarter worth approximately $60,000. Rhumbline Advisers grew its position in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares during the period. Finally, Ameriprise Financial Inc. purchased a new stake in Kyverna Therapeutics during the 3rd quarter valued at $77,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.